Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hubert G M Leufkens

Showing results (1-10 of 250) with videos related to

Pageof 25
Sort By:
Pharmacoepidemiology and Drug Safety|August 12, 2014
Regulatory decision-making: are we getting it right?Stephen J W Evans, Hubert G M Leufkens
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|May 30, 2026
European Science for Health Research Needs and PrioritiesMareike Lutz, Tessa Moleman, Hubert G M Leufkens
European Journal of Cancer (Oxford, England : 1990)|January 9, 2010
Therapeutic indications in oncology: emerging features and regulatory dynamicsGiovanni Tafuri, Hubert G M Leufkens, Richard Laing, et al.
Frontiers in Pharmacology|October 5, 2020
Getting the Right Evidence After Drug ApprovalRick A Vreman, Hubert G M Leufkens, Aaron S Kesselheim
American Journal of Respiratory and Critical Care Medicine|June 27, 2003
Inhaled corticosteroids and hip fracture: disease or drugs?Tjeerd P van Staa, Hubert G M Leufkens, Cyrus Cooper
British Journal of Clinical Pharmacology|August 16, 2012
Disclosure of grounds of European withdrawn and refused applications: a step forward on regulatory transparencyGiovanni Tafuri, Francesco Trotta, Hubert G M Leufkens, et al.
Bulletin of the World Health Organization|November 28, 2006
Rare essentials: drugs for rare diseases as essential medicinesPieter Stolk, Marjolein J C Willemen, Hubert G M Leufkens
Drug Safety|September 3, 2009
Pharmacovigilance of biopharmaceuticals: challenges remainThijs J Giezen, Aukje K Mantel-Teeuwisse, Hubert G M Leufkens
The American Journal of Cardiology|December 31, 2002
QTc-prolonging drugs and hospitalizations for cardiac arrhythmiasMarie L De Bruin, Arno W Hoes, Hubert G M Leufkens
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|July 5, 2025
Challenges and opportunities of adding CFTR modulators for cystic fibrosis to the WHO essential medicines listEnrico Costa, Hendrika A van den Ham, Hubert G M Leufkens
Pageof 25

Showing results (1-10 of 250) with videos related to

Sort By:
Pageof 25
Pharmacoepidemiology and Drug Safety|August 12, 2014
Regulatory decision-making: are we getting it right?Stephen J W Evans, Hubert G M Leufkens
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|May 30, 2026
European Science for Health Research Needs and PrioritiesMareike Lutz, Tessa Moleman, Hubert G M Leufkens
European Journal of Cancer (Oxford, England : 1990)|January 9, 2010
Therapeutic indications in oncology: emerging features and regulatory dynamicsGiovanni Tafuri, Hubert G M Leufkens, Richard Laing, et al.
Frontiers in Pharmacology|October 5, 2020
Getting the Right Evidence After Drug ApprovalRick A Vreman, Hubert G M Leufkens, Aaron S Kesselheim
American Journal of Respiratory and Critical Care Medicine|June 27, 2003
Inhaled corticosteroids and hip fracture: disease or drugs?Tjeerd P van Staa, Hubert G M Leufkens, Cyrus Cooper
British Journal of Clinical Pharmacology|August 16, 2012
Disclosure of grounds of European withdrawn and refused applications: a step forward on regulatory transparencyGiovanni Tafuri, Francesco Trotta, Hubert G M Leufkens, et al.
Bulletin of the World Health Organization|November 28, 2006
Rare essentials: drugs for rare diseases as essential medicinesPieter Stolk, Marjolein J C Willemen, Hubert G M Leufkens
Drug Safety|September 3, 2009
Pharmacovigilance of biopharmaceuticals: challenges remainThijs J Giezen, Aukje K Mantel-Teeuwisse, Hubert G M Leufkens
The American Journal of Cardiology|December 31, 2002
QTc-prolonging drugs and hospitalizations for cardiac arrhythmiasMarie L De Bruin, Arno W Hoes, Hubert G M Leufkens
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|July 5, 2025
Challenges and opportunities of adding CFTR modulators for cystic fibrosis to the WHO essential medicines listEnrico Costa, Hendrika A van den Ham, Hubert G M Leufkens
Pageof 25